Search Results

You are looking at 1 - 10 of 1,462 items for :

  • Refine by Access: Content accessible to Me x
Clear All
Full access

Surgery for Early-Stage Small Cell Lung Cancer

Bryan J. Schneider, Ashish Saxena, and Robert J. Downey

Committee recommended that the TNM staging system be used to stage SCLC in both routine practice and clinical trial design. 4 The standard treatment for LS-SCLC is definitive chemoradiation therapy without surgery; however, whether surgery has a role in

Full access

Association Between Frailty and Time Alive and At Home After Cancer Surgery Among Older Adults: A Population-Based Analysis

Julie Hallet, Bourke Tillman, Jesse Zuckerman, Matthew P. Guttman, Tyler Chesney, Alyson L. Mahar, Wing C. Chan, Natalie Coburn, Barbara Haas, and members of the Recovery after Surgical Therapy for Older adults Research–Cancer (RESTORE-Cancer) Group

Background Older adults have the highest incidence of cancer and represent the fastest growing group of individuals requiring cancer surgery. 1 – 3 Shared decision-making with older adults, in particular regarding surgery, has inherent

Full access

Surgery for Ovarian Cancer: Rationale and Guidelines

Benjamin E. Greer, Ron E. Swensen, and Heidi J. Gray

experience . J Clin Oncol 1991 ; 9 : 1138 – 1150 . 19 Hacker NF Berek JS Lagasse LD . Primary cytoreductive surgery for epithelial ovarian cancer . Obstet Gynecol 1983 ; 61 : 413 – 420 . 20 Hoskins WJ Bundy BN Thigpen JT . The

Full access

Surgery in the Management of Small Cell Lung Cancer

Robert J. Downey and Lee M. Krug

. Philadelphia, PA : Lippincott Williams and Wilkins , 2000 . 2 Passlick B . Can surgery improve local control in small cell lung cancer? Lung Cancer 2001 ; 33 ( Suppl 1 ): S147 – S151 . 3 Kohman LJ . Is there a place for surgery in

Full access

Optimal Management of Localized Renal Cell Carcinoma: Surgery, Ablation, or Active Surveillance

David Y. T. Chen and Robert G. Uzzo

Edited by Kerrin G. Robinson

Viterbo R Greenberg RE Al-Saleem T Uzzo RG . Prior abdominal surgery and radiation do not complicate the retroperitoneoscopic approach to the kidney or adrenal gland . J Urol 2005 ; 174 : 446 – 450 . 14 Nelson CP Wolf JS Jr . Comparison

Full access

Role of Locoregional Treatment in Vulvar Cancer With Pelvic Lymph Node Metastases: Time to Reconsider FIGO Staging?

Ashwin Shinde, Richard Li, Arya Amini, Yi-Jen Chen, Mihaela Cristea, Wenge Wang, Mark Wakabyashi, Ernest Han, Catheryn Yashar, Kevin Albuquerque, Sushil Beriwal, and Scott Glaser

Cancer suggest consideration of radiation therapy (RT) with concurrent chemotherapy in larger T2 or T3 lesions not amenable to up-front organ-sparing surgery. 3 However, minimal published data, either retrospective or prospective, exists for patients

Full access

Multimodality Approaches to Localized Gastric Cancer

Prajnan Das, Yixing Jiang, Jeffrey H. Lee, Manoop S. Bhutani, William A. Ross, Paul F. Mansfield, and Jaffer A. Ajani

positive peritoneal cytology, who represent a high-risk subgroup, and identify the 20% to 30% of patients with presumed localized cancer who in fact have low-volume peritoneal disease. 13 , 14 Surgery Surgery is the primary treatment for localized

Full access

Impact of Surgical Resection on Survival Outcomes After Chemoradiotherapy in Anal Adenocarcinoma

Richard Li, Ashwin Shinde, Marwan Fakih, Stephen Sentovich, Kurt Melstrom, Rebecca Nelson, Scott Glaser, Yi-Jen Chen, Karyn Goodman, and Arya Amini

recommendations. No randomized trials exist, and the results of small retrospective case series have led to contradictory conclusions. A study by the Rare Cancer Network showed improved survival with CRT alone compared with surgery/radiotherapy (RT) or surgery

Full access

Disparities in the Use of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma

Jordan M. Cloyd, Chengli Shen, Heena Santry, John Bridges, Mary Dillhoff, Aslam Ejaz, Timothy M. Pawlik, and Allan Tsung

recurrent disease. Although adjuvant chemotherapy improves survival for all patients with resected PDAC, 2 , 3 up to 50% of patients will not initiate postoperative chemotherapy, typically because of poor performance status after major surgery. 4 – 6 A

Full access

Treating Second Breast Events After Breast-Conserving Surgery for Ductal Carcinoma in Situ

Michael J. Hassett, Wei Jiang, Melissa E. Hughes, Stephen Edge, Sara H. Javid, Joyce C. Niland, Richard Theriault, Yu-Ning Wong, Deborah Schrag, and Rinaa S. Punglia

As the incidence of ductal carcinoma in situ (DCIS) has increased, so has the number of DCIS survivors. 1 Most patients with DCIS are treated with breast-conserving surgery (BCS). 2 Radiation therapy (RT) and antiestrogen therapy (AET) have been